SCHEMBL18137652

SCHEMBL18137652

CCOC(=O)c1cc(Cl)c(Cl)c(C(=O)OCC)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLP1R P43220 1/20 0.50
CYP1A2 P05177 1/20 0.50
ALDH1A1 P00352 3/20 0.48
NPC1 O15118 2/20 0.48
MAPT P10636 2/20 0.48
TP53 P04637 1/20 0.48
XBP1 P17861 1/20 0.48
MAPK1 P28482 1/20 0.48
HTT P42858 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HSD17B10 Q99714 1/20 0.48
TLR9 Q9NR96 1/20 0.48
KDM5B Q9UGL1 1/20 0.47
GABRA2 P47869 9/20 0.46
GABRB2 P47870 9/20 0.46
NOTUM Q6P988 1/20 0.44
TARBP2 Q15633 1/20 0.43
MEN1 O00255 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19951147 0.87 CYP1A2 (0.47) GLP1RCYP1A2ALDH1A1NPC1MAPT
SCHEMBL10382598 0.87 ALDH1A1 (0.50) GLP1RCYP1A2ALDH1A1NPC1MAPT
SCHEMBL18132216 0.86 CYP1A2 (0.46) GLP1RCYP1A2ALDH1A1NPC1MAPT
SCHEMBL18132275 0.84 CYP1A2 (0.45) GLP1RCYP1A2ALDH1A1NPC1MAPT
SCHEMBL18137436 0.83 GLP1R (0.47) GLP1RCYP1A2ALDH1A1NPC1MAPT
SCHEMBL18137437 0.83 CYP1A2 (0.46) GLP1RCYP1A2ALDH1A1NPC1MAPT
SCHEMBL18137428 0.83 CYP1A2 (0.46) GLP1RCYP1A2ALDH1A1NPC1MAPT
SCHEMBL18137434 0.83 GLP1R (0.47) GLP1RCYP1A2ALDH1A1NPC1MAPT
SCHEMBL19951135 0.81 CYP1A2 (0.45) GLP1RCYP1A2ALDH1A1NPC1MAPT
SCHEMBL18137651 0.81 GLP1R (0.46) GLP1RCYP1A2ALDH1A1NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107531693-B 5 or 8-substituted imidazo [1, 5-a ] pyridines as indoleamine, tryptophan dioxygenase inhibitors 百济神州有限公司 2021-07-06 CN disclosed
EP-3280715-B1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES BEIGENE LTD (KY) 2020-11-25 EP disclosed
EP-3280715-B1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES BEIGENE LTD (KY) 2020-11-25 EP disclosed
US-10647714-B2 5 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenases BEIGENE, LTD. (KY) 2020-05-12 US disclosed
CN-110872289-A Novel 8-substituted imidazo [1,5-a ] pyridines as IDO1 and/or TDO inhibitors 百济神州(北京)生物科技有限公司 2020-03-10 CN disclosed
US-20190284184-A1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO[1,5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2,3-DIOXYGENASES BEONE MEDICINES I GMBH (CH) 2019-09-19 US disclosed
US-10280163-B2 5 or 8-substituted imidazo[1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenases BEIGENE, LTD. (KY) 2019-05-07 US disclosed
US-10280163-B2 5 or 8-substituted imidazo[1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenases BEIGENE, LTD. (KY) 2019-05-07 US disclosed
US-20180072716-A1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO[1, 5-a] PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES BEONE MEDICINES I GMBH (CH) 2018-03-15 US disclosed
US-20180072716-A1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO[1, 5-a] PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES BEONE MEDICINES I GMBH (CH) 2018-03-15 US disclosed
US-20180072716-A1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO[1, 5-a] PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES BEONE MEDICINES I GMBH (CH) 2018-03-15 US disclosed
WO-2016161960-A1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES BEIGENE, LTD. (KY) 2016-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10280163-B2 5 or 8-substituted imidazo[1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenases IDO1, TPH1, IDO2 GLP1R 1020/4885CYP1A2 66/4885ALDH1A1 466/4885
US-10647714-B2 5 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenases IDO1, TPH1, IDO2 GLP1R 1020/4885CYP1A2 66/4885ALDH1A1 466/4885
US-20190284184-A1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO[1,5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2,3-DIOXYGENASES IDO1, TPH1, IDO2 GLP1R 976/4885CYP1A2 72/4885ALDH1A1 434/4885
US-20180072716-A1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO[1, 5-a] PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES IDO1, TPH1, IDO2 GLP1R 968/4885CYP1A2 72/4885ALDH1A1 440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.